<DOC>
	<DOCNO>NCT00022672</DOCNO>
	<brief_summary>This 2 arm study assess safety efficacy add intravenous trastuzumab ( Herceptin® ) daily oral anastrozole ( Arimidex® ) tablets first- second-line treatment postmenopausal patient human epidermal growth factor receptor-2 ( HER2 ) overexpressing metastatic breast cancer ( ER+ve and/or PR+ve ) . Patients randomize receive either anastrazole 1 mg per o ( po ) daily , anastrazole 1 mg po daily + load dose Herceptin® 4 mg/kg intravenous ( iv ) follow weekly dos Herceptin® 2 mg/kg iv . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Herceptin® ( Trastuzumab ) Combination With Arimidex® ( Anastrozole ) Aromatase Inhibitor Compared Arimidex® Alone Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>postmenopausal woman ; metastatic breast cancer suitable endocrine therapy ; positive hormone receptor status ; Human epidermal growth factor receptor 2 ( HER2 ) overexpression . patient hormone replacement therapy ; previous chemotherapy metastatic disease ; uncontrolled cardiac disease history cardiac failure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>